Research Library
RETA GLP-3 research
6 articles to explore, with links to 7 original sources.
About RETA GLP-3
RETA GLP-3 is a research peptide listing associated with GLP-1, GIP, and glucagon receptor investigations.
Understand the science
How two retatrutide trials counted breathing interruptions during sleep
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. “RETA GLP-3” is a catalog label. Its number does not name a receptor target. A 2026 report examined retatrutide in adults with moderate to severe obstructive sleep apnea.
3 sources (2025, 2026)
Explore study findings
What TRIUMPH-1 established about average weight change
Retatrutide activates the GIP, GLP-1 and glucagon receptors, the three targets behind its description as a triple agonist. The “GLP-3” catalog wording refers to the entry, while the scientific names identify the receptors studied.
2 sources (2025, 2026)
Why TRIUMPH-2 enrolled adults with type 2 diabetes
Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight.
2 sources (2026)
What retatrutide blood samples reveal about changing fuel use
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” label refers to the catalog entry.
1 source (2026)
Check methods and identity
What a three-sample retatrutide analysis showed about labeling
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” wording is a catalog label. A 2026 Australian paper examined a different question from the clinical trials.
2 sources (2026)
What the first TRANSCEND diabetes trial measured
Retatrutide is an investigational peptide that acts at GIP, GLP-1 and glucagon receptors. The catalog’s “GLP-3” wording describes this entry rather than a receptor.
2 sources (2026)
